Tetra Pharm Technologies

Executive Summary

Tetra Pharm Technologies is a Danish biopharmaceutical company developing novel small-molecule therapies for central nervous system (CNS) and immune-mediated disorders. The company leverages its proprietary ZYNDIKATE® drug delivery platform to enhance bioavailability and target specificity, with an internal pipeline addressing neurological and psychiatric conditions. Additionally, Tetra Pharm offers end-to-end CDMO services, utilizing ZYNDIKATE® to assist partners in overcoming formulation challenges. Founded in 2017 and headquartered in Copenhagen, the company operates as a private entity with a dual focus on internal R&D and service revenue. While specific pipeline assets are not disclosed, Tetra Pharm's platform technology and CDMO capabilities position it to capture value in the competitive CNS space.

Upcoming Catalysts (preview)

• Q4 2026Lead program preclinical/Phase I data readout50% success
• Q3 2026CDMO partnership or service contract award70% success
• Q1 2027Series A or B funding round60% success